Clinical study demonstrates rapid IL-4Rα inhibition and targeted suppression of skin-homing T cells in atopic dermatitis, indicating preserved systemic T helper cell balance.
T cells at week 4. No evidence of general T helper type cell skewing following a year of dupilumab treatment was found. In summary, dupilumab treatment rapidly and stably inhibited IL-4Rα, which was accompanied by a strong early functional immunological effect specifically on skin-homing T cells without affecting overall T helper type cell skewing in the long term.
No takes yet. Share an insight, caveat, or question.
Bakker et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: